Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
Outline of Final Research Achievements |
It has been known that human pluripotent stem cells undergo genomic instability due to artificial stimuli such as continuous culture and differentiation induction. In this study, in order to ensure the safety of human pluripotent stem cells that can be used for clinical applications, we aimed to clarify the difference between "harmless genetic mutations" and "potentially harmful genetic mutations". We detected the DNA mutations that arose during cell culture and showed that some mutations directly or indirectly might confer a selective growth advantage to the cell.
|